Success of Ozempic kidney failure trials proves disastrous for dialysis stocks

<img width="250" height="167" src="https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-250×167.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="" decoding="async" style="float: left; margin-right: 5px;" link_thumbnail="" srcset="https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-250×167.jpg 250w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-700×466.jpg 700w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-768×512.jpg 768w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-120×80.jpg 120w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-245×163.jpg 245w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-500×333.jpg 500w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819.jpg 1255w" sizes="(max-width: 250px) 100vw, 250px" /><p><span data-contrast="auto">The company indicated the trial would come to an end, approximately a year before scheduled completion, following a recommendation from an independent data monitoring committee. Ozempic, a treatment commonly used for Type 2 Diabetes, contains semaglutide. The trial aimed to discover if it could stem the progress of kidney disease and help with associated complications.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">After the public statement, Novo Nordisk shares rose by 2.5% during extended trading. Other companies in the kidney business experienced the opposite.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">On Wednesday, DaVita (DVA.N) shares plummeted by 16% to around $72.62 per share. The stock of its German nemesis, Fresenius Medical (FMEG.DE), also came under the knife and dropped by 16.7% to approximately $14.44 a share.</span></p>
<hr />
<p><a href="https://finaffiliates.us20.list-manage.com/subscribe/post?u=e0dd4d77c259eb270712a4eeb&amp;id=fd200b8f75&amp;v_id=4291&amp;f_id=00946ce6f0" target="_blank" rel="noopener"><em>Don’t miss out the latest news, subscribe to LeapRate’s newsletter</em></a></p>
<hr />
<p><span data-contrast="auto">Similarly, associated markets, such as Baxter International (BAX.N), that produces items used in dialysis therapies, also suffered. This particular company’s shares dropped by 5.8% to roughly $35.14.</span><span data-ccp-props="{}"> </span></p>
<p><span data-contrast="auto">Experts stated that the dialysis industry gained its many riches from the high prevalence of diabetes and obesity, which greatly contribute to kidney problems. However, Novo’s Ozempic and Wegovy, a drug widely used to treat obesity, significantly bettered these conditions. In its media statement, Novo said:</span><span data-ccp-props="{}"> </span></p>
<blockquote><p><span data-contrast="auto">Based on the decision to stop the trial at interim, the process of closing the trial will be initiated. To protect the integrity of the trial, Novo Nordisk remains blinded to the results until trial completion.</span></p></blockquote>
<p>The post <a rel="nofollow" href="https://www.leaprate.com/news/success-of-ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks/">Success of Ozempic kidney failure trials proves disastrous for dialysis stocks</a> appeared first on <a rel="nofollow" href="https://www.leaprate.com">LeapRate</a>.</p>